Pediatric Hematology Oncology Journal最新文献

{"title":"Editorial Board Information","authors":"","doi":"10.1016/S2468-1245(26)00069-0","DOIUrl":"10.1016/S2468-1245(26)00069-0","url":null,"abstract":"","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 3","pages":"Article 100871"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149003937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Board Information","authors":"","doi":"10.1016/S2468-1245(26)00047-1","DOIUrl":"10.1016/S2468-1245(26)00047-1","url":null,"abstract":"","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 2","pages":"Article 100849"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148365760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric idiopathic multicentric Castleman disease presenting with massive ascites and pleural effusions","authors":"Kevin Marzotto ,&nbsp;Chelsea Haynes ,&nbsp;Dragos Luca ,&nbsp;Jennifer Welch ,&nbsp;Dana Egan-Sherry","doi":"10.1016/j.phoj.2026.100839","DOIUrl":"10.1016/j.phoj.2026.100839","url":null,"abstract":"<div><div>Castleman disease is a rare lymphoproliferative disorder with varying clinical presentations. In pediatric populations, the incidence of idiopathic multicentric Castleman disease (iMCD) is exceedingly rare, with literature limited to isolated case reports and case series. Herein, we describe a 14-year-old female who presented with massive ascites, pleural effusions, and diffuse lymphadenopathy found to have iMCD. This unusual presentation of pediatric iMCD is similar to adult TAFRO subtype, but without severe thrombocytopenia. After a limited treatment course of rituximab and prednisone, the patient achieved complete remission.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 2","pages":"Article 100839"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148185057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax–azacitidine as a bridge to transplant in pediatric relapsed/refractory acute myeloid leukemia: A real-world experience","authors":"Sunisha Arora ,&nbsp;Anuj Singh ,&nbsp;Sohini Chakraborty ,&nbsp;Vaibhav Chadha ,&nbsp;Satyendra Batra ,&nbsp;Parminder Pal Singh ,&nbsp;Neha Rastogi Panda ,&nbsp;Shrinidhi Nathany ,&nbsp;Madhur Arora ,&nbsp;Anusha Swaminathan ,&nbsp;Surbhi Pokhriyal ,&nbsp;Aastha Gupta ,&nbsp;Surbhi Singh ,&nbsp;Bharti Sharma ,&nbsp;Rahul Bhargava ,&nbsp;Vikas Dua","doi":"10.1016/j.phoj.2026.100837","DOIUrl":"10.1016/j.phoj.2026.100837","url":null,"abstract":"<div><h3>Background</h3><div>Survival outcomes in pediatric acute myeloid leukemia (AML) have improved significantly; however, prognosis for relapsed or refractory (R/R) disease remains dismal. This study evaluates real-world outcomes of Venetoclax-Azacytidine (Ven–Aza) as a bridge to transplant in children with R/R AML.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed patients aged 1–18 years with R/R AML treated with Ven–Aza at a single centre (January 2022–December 2025). Treatment consisted of Aza (75 mg/m², days 1–7) and Ven with a 3-day ramp-up to body surface area–adjusted adult exposure equivalent dosing for 14 days. Responses, adverse events and survival outcomes were analysed.</div></div><div><h3>Results</h3><div>Fourteen patients received Ven–Aza. Median number of Ven-Aza cycles administered were 2 (Range:1-4). Best responses achieved were CR in 6 (42.8%), CRi in 2 (14.2%), PR in 1 (7.1%) and NR in 5 (35.7%), giving a composite CR/CRi of 8/14 (57.1%) and ORR of 9/14 (64.3%). MRD negativity occurred in 6 of 8 responders. Patients harbouring <em>RUNX1</em> mutations showed favourable responses (CR/CRi in 4/6). Meanwhile, patients with <em>FLT3-ITD</em> (n = 5), <em>TP53</em> (n = 1) or <em>KRAS/NRAS</em> (n = 2) alterations demonstrated lower response rates and a higher likelihood of disease progression. All 8 patients with CR/CRi underwent allogenic HSCT at a median of 2.5 months. Hematologic toxicities were frequent (grade ≥3 in 11); infectious complications occurred in 5 and TLS in 2 patients. Median follow-up was 10 months; 2- years OS was 28.6% (95th CI: 0.08-0.52) for whole cohort and 57.1% (95th centile: 0.17-0.83) for the patients undergoing HSCT.</div></div><div><h3>Conclusion</h3><div>Ven-aza demonstrated encouraging remission rates and acceptable toxicity in pediatric R/R AML, effectively serving as a bridge to HSCT.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 2","pages":"Article 100837"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148185056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional status during initial childhood cancer treatment: A retrospective cohort study","authors":"Kalpana Gupta ,&nbsp;Ramandeep Singh Arora ,&nbsp;Karuna Singh ,&nbsp;Harit Kumar Chaturvedi ,&nbsp;Ritika Samaddar","doi":"10.1016/j.phoj.2026.100835","DOIUrl":"10.1016/j.phoj.2026.100835","url":null,"abstract":"<div><h3>Background</h3><div>Malnutrition is a common problem in pediatric oncology. However, most studies only measure weight at diagnosis and the end of treatment, missing the critical early period. This study aimed to track month-by-month nutritional changes during the first 60 days of chemotherapy to identify when weight loss occurs.</div></div><div><h3>Methods</h3><div>We analyzed medical records of 130 children (aged 0–18 years) treated for cancer. Anthropometric data (height and weight) were collected at diagnosis (TM0), one month (TM1), and two months (TM2). Nutritional status was assessed using weight-for-height Z-scores for children &lt;5 years and BMI-for-age Z-scores for those ≥5 years, harmonized into a single WHZ/BMIZ variable based on World Health Organization standards. Longitudinal changes in continuous Z-scores were analyzed using the Friedman test, while changes in categorical malnutrition prevalence were assessed using Cochran's Q test.</div></div><div><h3>Results</h3><div>The study included 130 patients (63.8% male). The mean WHZ/BMIZ score declined from −0.18 at diagnosis to −0.46 at one month, before recovering to −0.10 at two months; this change was not statistically significant (p = 0.156). The overall prevalence of malnutrition (moderate and severe acute malnutrition combined) remained stable across time points (p = 0.840). However, severe acute malnutrition peaked transiently at one month (16.2%) before returning to baseline. Subgroup analysis revealed that adolescents aged 10–14 years were the only group to experience a statistically significant nutritional decline (p = 0.009).</div></div><div><h3>Conclusion</h3><div>Overall nutritional status remained stable during the first 60 days of cancer treatment; however, specific vulnerabilities were identified. Adolescents aged 10–14 years experienced significant nutritional deterioration, and a transient peak in severe acute malnutrition was observed at one month. Targeted nutritional monitoring and early intervention should focus on these high-risk groups and timeframes.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 2","pages":"Article 100835"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148185058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor volume reduction after neoadjuvant chemotherapy in childhood nephroblastoma: radiological, histopathological, and clinical correlates in Tanzania","authors":"Tumaini Mtui ,&nbsp;Clement Kalambo ,&nbsp;Esther Majaliwa ,&nbsp;Heronima Kashaigili ,&nbsp;Vincent Odhiambo ,&nbsp;Felister Uisso ,&nbsp;Adnan Sadiq","doi":"10.1016/j.phoj.2026.100836","DOIUrl":"10.1016/j.phoj.2026.100836","url":null,"abstract":"<div><h3>Background</h3><div>Nephroblastoma is the most common pediatric kidney cancer, accounting for approximately 6% of childhood malignancies. Neoadjuvant chemotherapy plays an important role in reducing tumor size and facilitating safer surgery. This study aimed to determine radiological tumor volume reduction in nephroblastoma after neoadjuvant chemotherapy and its associations with histopathological subtypes and clinical outcomes among children in a lower-middle income country (Tanzania).</div></div><div><h3>Material and methods</h3><div>A retrospective cohort study was conducted among 126 children aged 6 months to &lt;18 years with histopathologically confirmed nephroblastoma treated under the International Society of Pediatric Oncology (SIOP) umbrella protocol diagnosed at two tertiary oncology centers in Tanzania between Jan. 2021 and Dec. 2023. Tumor volumes were measured from pre- and post-neoadjuvant chemotherapy abdominal pelvic computed tomography scans to calculate volume reduction ratios. SPSS v26 was used for analysis, with logistic regression and chi-square tests used to assess associations with histopathology and clinical outcomes.</div></div><div><h3>Results</h3><div>The median age at diagnosis was 36 months, with female predominance (57.9%), and most lacked health insurance (71.4%). Blastemal histological subtype was the most common subtype (40.5%). Post neoadjuvant chemotherapy, 62.7% of patients achieved a good response, while 40.5% had residual tumor volumes &gt;500 ml. Stromal histology was strongly associated with large residual (AOR = 15.00; 95% CI: 4.00–56.13; p &lt; 0.001). Tumor volume reduction also varied by treatment center and insurance status.</div></div><div><h3>Conclusion</h3><div>Histopathological subtypes are key determinants of the radiological response following neoadjuvant chemotherapy. Differences by treatment center and insurance status suggest that healthcare-related factors also influence outcomes, although the treatment center effect showed borderline statistical significance. Further large-scale studies are needed to clarify these associations in resource-limited settings.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 2","pages":"Article 100836"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leveraging South-South cooperation to strengthen public health policies in childhood cancer care: Insights from the St Jude Global Alliance Convening","authors":"Liliana Vasquez ,&nbsp;Julia Palma ,&nbsp;Claudia Pascual ,&nbsp;Sofía Aljaro ,&nbsp;Luis Beingolea ,&nbsp;Maria del Carmen Calle ,&nbsp;Carlos Rodriguez-Galindo","doi":"10.1016/j.phoj.2026.100814","DOIUrl":"10.1016/j.phoj.2026.100814","url":null,"abstract":"<div><h3>Background</h3><div>South-South cooperation is an increasingly recognized approach to strengthen health systems through the horizontal exchange of knowledge, resources, and technologies between countries with similar contexts. In Latin America, this model holds great potential for addressing critical gaps in childhood cancer care. A dedicated session during the 2024 St. Jude Global Alliance Convening brought together global stakeholders to explore how South-South collaboration can support the development and implementation of equitable public health policies for childhood cancer. The session used the WHO CureAll framework to guide discussions across four priority pillars of action.</div></div><div><h3>Methods</h3><div>Organized by the Pan American Health Organization (PAHO) and St. Jude Children's Research Hospital, the session engaged over 40 participants in a 75-min collaborative workshop. Attendees were divided into four groups aligned with the CureAll pillars: (1) Centers of Excellence, (2) Universal Health Coverage, (3) Regimens for Management, and (4) Evaluation and Monitoring. Through guided exercises, each group identified shared regional challenges and proposed actionable, cooperative solutions based on existing or potential examples of South-South cooperation. Findings were presented in a final plenary discussion.</div></div><div><h3>Results</h3><div>Participants identified multiple shared challenges across the CureAll pillars, including insufficient specialized human resources, lack of coordinated referral systems, limited access to essential medicines, and the absence of standardized protocols and pediatric cancer registries. In response, groups proposed regional training programs, joint development of treatment guidelines, telemedicine platforms, and cross-country referral pathways for complex treatments such as hematopoietic stem cell transplantation. Examples of successful South-South initiatives at a global level—including collaborative campaigns for early diagnosis and regional policy dialogues—demonstrated the viability and impact of this cooperation model.</div></div><div><h3>Conclusions</h3><div>The session reinforced the relevance of South-South cooperation as a strategic approach to advancing childhood cancer care in the region. By fostering peer learning, policy alignment, and resource sharing, countries can co-develop sustainable solutions to common challenges. The experience highlighted the power of regional collaboration to inform policy, build capacity, and reduce health disparities in pediatric oncology.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 1","pages":"Article 100814"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147397791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Twenty-years of hematopoietic stem cell transplantation in childhood acute myeloid leukemia: a single-center study from South India","authors":"Shyam Sundar Sah ,&nbsp;Abhishek Kumbhalwar","doi":"10.1016/j.phoj.2026.100811","DOIUrl":"10.1016/j.phoj.2026.100811","url":null,"abstract":"","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 1","pages":"Article 100811"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147397792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The “good” future is a mirage? – hyperdiploidy in childhood acute lymphoblastic leukemia","authors":"Vijayshree Muthukumar ,&nbsp;Indhumathi Nagarathinam ,&nbsp;Kavitha Ganesan ,&nbsp;Ramya Uppuluri ,&nbsp;Revathi Raj","doi":"10.1016/j.phoj.2026.100805","DOIUrl":"10.1016/j.phoj.2026.100805","url":null,"abstract":"","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 1","pages":"Article 100805"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147397794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatic malignant transformation of teratoma in children and adolescents - Case series with literature review","authors":"Yamini Krishnan ,&nbsp;Smitha Bhaskaran ,&nbsp;Venma Jojo ,&nbsp;Pavitra Subramanian ,&nbsp;Gazel S. ,&nbsp;Krishnan V.P.","doi":"10.1016/j.phoj.2025.100800","DOIUrl":"10.1016/j.phoj.2025.100800","url":null,"abstract":"<div><div>Somatic malignant transformation (SMT) is defined as the development of non germ cell malignant neoplasm within a teratoma. Malignant change can occur in any of the various components of the three germ cell layers. In adults, more than 80 % of all malignant transformations are squamous cell carcinoma, the rest being adenocarcinoma and carcinoid tumor. In children, SMT are very uncommon and reports are limited.</div><div>We report a case series of three children who presented with SMT of a teratoma. We also undertook a literature search of published reports on SMT in children.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 1","pages":"Article 100800"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145980995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}